Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

The Lancet. Respiratory Medicine
K SchnippelF Conradie

Abstract

Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline. In this retrospective cohort study, we analysed patient data from the South African rifampicin-resistant tuberculosis case register (EDRweb), and identified additional mortality using the national vital statistics register. We excluded patients who started treatment before July 1, 2014, or after March 31, 2016; patients younger than 15 years or older than 75 years; patients without documented rifampicin resistance, and patients with pre-extensively drug-resistant tuberculosis (multidrug-resistant tuberculosis with further resistance to a second-line injectable or fluoroquinolone). We compared all-cause mortality between patients...Continue Reading

Citations

Aug 4, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Ana-Maria IonescuAdrian Thomas
Sep 27, 2018·The New England Journal of Medicine·Helen Cox, Valerie Mizrahi
Jan 17, 2019·Expert Review of Respiratory Medicine·Jennifer Furin
Oct 6, 2018·The European Respiratory Journal·Neel R GandhiN Sarita Shah
Mar 14, 2019·The New England Journal of Medicine·Gavin J Churchyard
Mar 23, 2019·PLoS Medicine·Patrick P J PhillipsAndrew J Nunn
May 14, 2019·The Journal of Antimicrobial Chemotherapy·Sean WassermanGraeme Meintjes
May 30, 2019·The New England Journal of Medicine·Margaretha de VosHelen Cox
Jul 25, 2019·Expert Opinion on Drug Safety·Karen Cohen, Gary Maartens
May 18, 2019·The European Respiratory Journal·Irina VasilyevaUNKNOWN TMC207TBC3001 study group
Jul 3, 2019·Antimicrobial Agents and Chemotherapy·Arash GhodousiDaniela Maria Cirillo
Nov 16, 2019·American Journal of Respiratory and Critical Care Medicine·Payam NahidBarbara Seaworth
Dec 7, 2019·Expert Opinion on Drug Safety·Maddalena CerroneRobert J Wilkinson
Oct 18, 2019·The European Respiratory Journal·Olatunde OlayanjuKeertan Dheda
Mar 5, 2020·The New England Journal of Medicine·Francesca ConradieUNKNOWN Nix-TB Trial Team
Mar 7, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marian LovedayJames A Seddon
Feb 16, 2020·The European Respiratory Journal·Camus NimmoMax O'Donnell
Feb 14, 2020·American Journal of Respiratory and Critical Care Medicine·Sönke AndresFlorian P Maurer
May 31, 2020·The European Respiratory Journal·Norbert NdjekaGary Maartens
Jul 24, 2020·Future Microbiology·Lorenzo GuglielmettiJérôme Robert
Jul 15, 2020·Antimicrobial Agents and Chemotherapy·Nazir Ahmed IsmailShaheed V Omar
Apr 20, 2019·Emerging Infectious Diseases·Lawrence MbuagbawChristian Lienhardt
Sep 19, 2020·PloS One·Dzintars GothamErica Lessem
Dec 21, 2018·African Journal of Laboratory Medicine·Nazir IsmailPhilip C Onyebujoh
Sep 27, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sundari MaseNeha Shah
Jan 5, 2021·Expert Opinion on Pharmacotherapy·Marta Martín-García, Jaime Esteban
Jul 6, 2019·The Lancet. HIV·Graeme MeintjesGary Maartens
Feb 4, 2021·Medicina clínica·José Antonio Caminero LunaFelipe Rodríguez de Castro
Dec 11, 2020·Nature·Valerie Mizrahi, Clifton E Barry Iii
Jul 25, 2020·American Journal of Respiratory and Critical Care Medicine·Molly F FrankeCarole D Mitnick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Ying ZhaoSean Wasserman
The European Respiratory Journal
Ioana D OlaruChristoph Lange
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
N NdjekaY Pillay
© 2022 Meta ULC. All rights reserved